{"id":"troxacitabine","rwe":[],"tags":[{"label":"troxacitabine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Anti-HIV Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Anti-Retroviral Agents","category":"pharmacology"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Antiviral Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"troxatyl","offLabel":[],"synonyms":["troxacitabine","troxatyl","alpha-L-Dioxolane-C"],"timeline":[],"approvals":[],"brandName":"Troxatyl","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"troxacitabine","explanation":"Imagine your body's cells are like factories that make copies of themselves. Viruses are like tiny invaders that try to take over these factories. Troxacitabine stops the factories from making copies of the invaders by blocking the machines that make the copies.","oneSentence":"Troxacitabine works by inhibiting viral DNA polymerase, which is essential for viral replication.","technicalDetail":"Troxacitabine is a nucleoside analog that acts as a chain terminator, inhibiting viral DNA polymerase through its incorporation into the viral DNA strand, thereby preventing viral replication."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3635","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=TROXACITABINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TROXACITABINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T16:10:15.860717","biosimilars":[],"competitors":[],"genericName":"troxacitabine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07493668","phase":"PHASE2","title":"Fostrox Plus Lenvatinib vs Lenvatinib in Advanced Hepatocellular Carcinoma After First-line Immunotherapy","status":"NOT_YET_RECRUITING","sponsor":"CHA University","startDate":"2026-04-27","conditions":["Hepatocellular Carcinoma (HCC)"],"enrollment":80,"completionDate":"2029-04-27"},{"nctId":"NCT00012259","phase":"PHASE2","title":"Troxacitabine in Treating Patients With Chronic Myelogenous Leukemia","status":"COMPLETED","sponsor":"Shire","startDate":"2000-12-11","conditions":["Leukemia"],"enrollment":31,"completionDate":"2002-03-27"},{"nctId":"NCT00104468","phase":"PHASE1,PHASE2","title":"Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Refractory Acute Myelogenous Leukemia (AML)","status":"TERMINATED","sponsor":"SGX Pharmaceuticals, Inc.","startDate":"2003-04","conditions":["Acute Myelogenous Leukemia"],"enrollment":50,"completionDate":"2007-06"},{"nctId":"NCT00104286","phase":"PHASE1,PHASE2","title":"Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Solid Tumors","status":"TERMINATED","sponsor":"SGX Pharmaceuticals, Inc.","startDate":"2003-01","conditions":["Neoplasms"],"enrollment":50,"completionDate":"2005-11"},{"nctId":"NCT00129948","phase":"PHASE2","title":"Study for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)","status":"TERMINATED","sponsor":"SGX Pharmaceuticals, Inc.","startDate":"2005-07","conditions":["Leukemia, Myeloid, Acute"],"enrollment":211,"completionDate":"2007-10"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"60KQZ0388Y","CHEBI":"CHEBI:134886","INN_ID":"7886","UMLSCUI":"C0877874","ChEMBL_ID":"CHEMBL359164","KEGG_DRUG":"D06255","DRUGBANK_ID":"DB04961","PDB_CHEM_ID":" LTT","PUBCHEM_CID":"454194","MESH_SUPPLEMENTAL_RECORD_UI":"C074908"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"82.0 hours","clearance":"2.4 mL/min/kg","volumeOfDistribution":"1.0 L/kg"},"publicationCount":76,"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Troxacitabine is a small molecule used in clinical trials for various conditions, including Hepatocellular Carcinoma, Leukemia, and Neoplasms. It has been studied in combination with other interventions, such as Fostrox and Lenvatinib, in clinical trials.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}